Clinical Trial Update: Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab [Phase 3]

View source ↗

Summary

A Phase 3 trial update evaluating whether house dust mite SLIT tablets can sustain asthma control in patients with severe asthma who are treated with tezepeluma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• House Dust Mite Allergy

Drugs mentioned

• HDM Sublingual Immunotherapy Tablet (house dust mite SLIT tablet)
• Tezspire (tezepelumab)

Snippet

Sponsor: University Hospital, Montpellier | Conditions: Severe Asthma, Allergy to House Dust Mites | Phase 3 | Status: NOT_YET_RECRUITING